RT Journal Article
SR Electronic
T1 Sensitivity of unconstrained quantitative magnetization transfer MRI to Amyloid burden in preclinical Alzheimer’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.15.24305860
DO 10.1101/2024.04.15.24305860
A1 Mao, Andrew
A1 Flassbeck, Sebastian
A1 Marchetto, Elisa
A1 Masurkar, Arjun V.
A1 Rusinek, Henry
A1 Assländer, Jakob
YR 2024
UL http://medrxiv.org/content/early/2024/04/16/2024.04.15.24305860.abstract
AB Introduction Magnetization transfer MRI is sensitive to semi-solid macromolecules, including amyloid beta, and has been used to discriminate Alzheimer’s disease (AD) patients from controls. Here, we utilize an unconstrained 2-pool quantitative MT (qMT) approach that quantifies the longitudinal relaxation rates of free water and semi-solids separately, and investigate its sensitivity to amyloid accumulation in preclinical subjects.Methods We recruited 15 cognitively normal subjects, of which nine were amyloid positive by [18F]Florbetaben PET. A 12 min qMT scan was used to estimate the unconstrained 2-pool qMT parameters. Group comparisons and correlations were analyzed at the lobar level.Results The exchange rate and semi-solid pool’s were sensitive to the amyloid concentration. The former finding is consistent with previous reports in clinical AD, but the latter is novel as its value is typically constrained.Discussion qMT MRI may be a promising surrogate marker of amyloid beta without the need for contrast agents or radiotracers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH grants F30 AG077794, R01 NS131948, T32 GM136573, an NIA-funded Alzheimer's Disease Research Center (P30 AG066512), and was performed under the rubric of the Center for Advanced Imaging Innovation and Research (CAI2R), an NIBIB National Center for Biomedical Imaging and Bioengineering (P41 EB017183).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the New York University School of Medicine gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesN/AqMTquantitative magnetization transfer